Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA267439
Max Phase: Preclinical
Molecular Formula: C52H80N6O13
Molecular Weight: 997.24
Molecule Type: Small molecule
Associated Items:
ID: ALA267439
Max Phase: Preclinical
Molecular Formula: C52H80N6O13
Molecular Weight: 997.24
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O
Standard InChI: InChI=1S/C52H80N6O13/c1-6-8-9-10-11-12-13-14-15-16-17-18-22-25-42(62)56-45(34(4)59)51(69)57-44(33(3)7-2)49(67)58-46(35(5)60)50(68)54-39(30-36-23-20-19-21-24-36)47(65)53-40(32-43(63)64)48(66)55-41(52(70)71)31-37-26-28-38(61)29-27-37/h19-21,23-24,26-29,33-35,39-41,44-46,59-61H,6-18,22,25,30-32H2,1-5H3,(H,53,65)(H,54,68)(H,55,66)(H,56,62)(H,57,69)(H,58,67)(H,63,64)(H,70,71)/t33-,34+,35+,39-,40-,41-,44-,45-,46-/m0/s1
Standard InChI Key: UOKLNRZYPUXLRL-BDHQDBTNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 997.24 | Molecular Weight (Monoisotopic): 996.5783 | AlogP: 3.93 | #Rotatable Bonds: 36 |
Polar Surface Area: 309.89 | Molecular Species: ACID | HBA: 11 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.36 | CX Basic pKa: | CX LogP: 5.48 | CX LogD: -1.07 |
Aromatic Rings: 2 | Heavy Atoms: 71 | QED Weighted: 0.04 | Np Likeness Score: 0.22 |
1. Basse N, Papapostolou D, Pagano M, Reboud-Ravaux M, Bernard E, Felten AS, Vanderesse R.. (2006) Development of lipopeptides for inhibiting 20S proteasomes., 16 (12): [PMID:16630721] [10.1016/j.bmcl.2006.03.033] |
Source(1):